Which Wegovy dose do most people end up on?

Why 2.4 mg became the standard — and what changed in 2026

Wegovy's journey to 2.4 mg as the standard maintenance dose was deliberate. The titration schedule approved by the MHRA starts at 0.25 mg weekly for the first month, then steps to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, spending roughly four weeks at each level. The point of moving slowly isn't impatience management; it's about letting your gut adapt to a medicine that slows gastric emptying and adjusts appetite signals through the GLP-1 receptor. Rushing the schedule tends to make nausea and other gastrointestinal effects worse, not better.

For years, 2.4 mg was the ceiling. Then, on 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg pen (one pre-set weekly injection) for adults with a BMI of 30 or above. The MHRA's announcement of the 7.2 mg Wegovy pen noted average weight losses of around 20.7% over 72 weeks at that higher dose, approaching tirzepatide's results in comparable trials. The starting dose remains 0.25 mg; titration still happens under prescriber supervision. The 7.2 mg pen is not licensed for cardiovascular indications, and it isn't a shortcut, it's an option for people who tolerate the lower doses well and whose prescriber judges a further step appropriate.

If you're weighing up how these two doses compare on effectiveness, the question of which Wegovy dose is most effective unpacks the evidence more fully.

The dose most people actually reach, and the ones they spend less time on

In clinical practice, the lower doses in the Wegovy schedule are stepping stones, not destinations. The 0.25 mg and 0.5 mg pens exist to let your system find its footing; most people on the full titration pathway reach 2.4 mg within about five months. A smaller group may stay at 1.7 mg if side effects at 2.4 mg are difficult to manage, and that's a legitimate prescriber decision, not a treatment failure.

Since 2026, a proportion of patients who tolerate 2.4 mg well may progress to 7.2 mg. The majority of people who have been prescribed Wegovy over the last few years have spent the most time at 2.4 mg, simply because it was the only maintenance option available. As the 7.2 mg pen becomes more established, that balance may shift, but 2.4 mg remains the most prescribed maintenance dose right now.

One practical habit worth building: before each new pen, check the dose printed on the label against what your prescriber told you to expect. It takes under a minute and catches dispensing mix-ups early. If there's a discrepancy, call your pharmacy before injecting. A broader look at how the full range of available strengths fits together is covered on the guide to Wegovy doses and pen formats.

It's also worth knowing that the complete Wegovy dose overview explains how each step in the schedule is structured and what to expect at each stage.

What shapes your individual dose decision

No two people land on the same dose for identical reasons. A prescriber weighing up your Wegovy dose is looking at several things at once: how much weight you've lost at your current dose, how well you're tolerating it, your starting BMI, whether you have conditions that interact with the medicine, and the direction of travel over the months you've been using it.

NICE's guidance on semaglutide (TA875) recommends considering stopping if less than 5% weight loss has occurred after six months on the maintenance dose. That's not a punishment; it's a recognition that the medicine helps some people more than others, and clinical resources are best directed where they work. Your prescriber applies the same logic at each review, including dose-increase decisions.

Side effects play a role too. The most common are gastrointestinal: nausea, loose stools, stomach discomfort, and reflux tend to cluster around dose increases and usually ease within a couple of weeks. If they don't settle, a prescriber may hold the current dose longer before moving up, or consider whether the higher dose is appropriate at all. That conversation belongs with your clinical team, not a forum. The main Wegovy overview page covers side effects and what to expect across the treatment period.

Cost is a real factor for many people. Private Wegovy pricing varies by dose, provider, and what's included in the price. The Wegovy pricing page sets out honest market context so you know what questions to ask before committing to any service. At nume, a single transparent price covers your consultation, prescription, and next-working-day delivery, there are no subscription traps or automatic renewals.

When your dose might stay lower than expected

Some people find they lose meaningful weight before reaching 2.4 mg and their prescriber is comfortable holding there. That's not uncommon. The dose ladder is a guide, not a mandate; the right dose is the lowest one that achieves your clinical goals without causing side effects that undermine your daily life.

Equally, if a dose increase is clinically appropriate and you're wondering what the evidence says about outcomes further up the scale, the page on weight loss by Wegovy dose walks through what the trial data shows at each level.

If you'd like to discuss where you sit in this picture, speaking with a prescriber is the right next step. Our clinical team at nume reviews every consultation the same day, a real prescriber, not an automated filter. When you're ready, speak to our prescribers through a free consultation and get a clinical view on what's appropriate for you.